Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER: Pyridorin in diabetic nephropathy due to type 2 diabetes
2014-001641-24Phase 3Terminated
- Sponsor
- NephroGenex
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis comparing Pyridorin 300 mg BID with Placebo (2 arms). Primary endpoint: Primary composite renal endpoint. Started Jul 2014; status: terminated.
02
Drugs
pyridorin
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2014-001641-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001641-24.